Do analysts rate RENX or COG?

Cambridge Cognition has a consensus price target of GBX 56, indicating a potential upside of 63.50%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts plainly believe Cambridge Cognition is more favorable than Renalytix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Renalytix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cambridge Cognition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Does the media prefer RENX or COG?

In the previous week, Renalytix had 1 more articles in the media than Cambridge Cognition. MarketBeat recorded 2 mentions for Renalytix and 1 mentions for Cambridge Cognition. Cambridge Cognition's average media sentiment score of 0.67 beat Renalytix's score of -0.21 indicating that Cambridge Cognition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Renalytix 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Cambridge Cognition 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, RENX or FDBK?

Feedback has lower revenue, but higher earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Feedback, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Renalytix £3.30M 3.51 -£109.93M -£4.00 N/A Feedback £849.62K 3.35 -£10.84M -£15.74 N/A

Is RENX or FDBK more profitable?

Renalytix has a net margin of -680.00% compared to Feedback's net margin of -845.25%. Renalytix's return on equity of 274.67% beat Feedback's return on equity. Company Net Margins Return on Equity Return on Assets Renalytix -680.00% 274.67% -93.54% Feedback -845.25% -135.17% -22.99%

Which has higher valuation & earnings, IQAI or RENX?

IQ-AI has higher earnings, but lower revenue than Renalytix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IQ-AI £538.19K 3.30 N/A N/A N/A Renalytix £3.30M 3.51 -£109.93M -£4.00 N/A

Is IQAI or RENX more profitable?

IQ-AI has a net margin of -77.52% compared to Renalytix's net margin of -680.00%. Renalytix's return on equity of 274.67% beat IQ-AI's return on equity. Company Net Margins Return on Equity Return on Assets IQ-AI -77.52% -140.75% -22.03% Renalytix -680.00% 274.67% -93.54%

Which has preferable valuation & earnings, DVRG or RENX?

DeepVerge has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than DeepVerge, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DeepVerge £12.41M 0.00 -£2.46M -£0.01 N/A Renalytix £3.30M 3.51 -£109.93M -£4.00 N/A

Is DVRG or RENX more profitable?

DeepVerge has a net margin of -19.81% compared to Renalytix's net margin of -680.00%. Renalytix's return on equity of 274.67% beat DeepVerge's return on equity. Company Net Margins Return on Equity Return on Assets DeepVerge -19.81% -10.27% -5.56% Renalytix -680.00% 274.67% -93.54%

Renalytix (RENX) Competitors

GBX 2.65 +0.33 (+14.22%)

As of 11:44 AM Eastern

Compare

RENX vs. COG, INHC, FDBK, IQAI, and DVRG

Should you buy Renalytix stock or one of its competitors? MarketBeat compares Renalytix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Renalytix include Cambridge Cognition (COG), Induction Healthcare Group (INHC), Feedback (FDBK), IQ-AI (IQAI), and DeepVerge (DVRG). These companies are all part of the "health information services" industry.

How does Renalytix compare to Cambridge Cognition?

Renalytix (LON:RENX) and Cambridge Cognition (LON:COG) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

14.0% of Renalytix shares are held by institutional investors. Comparatively, 15.9% of Cambridge Cognition shares are held by institutional investors. 5.1% of Renalytix shares are held by insiders. Comparatively, 3.3% of Cambridge Cognition shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cambridge Cognition has a consensus price target of GBX 56, indicating a potential upside of 63.50%. Given Cambridge Cognition's stronger consensus rating and higher possible upside, analysts plainly believe Cambridge Cognition is more favorable than Renalytix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Renalytix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cambridge Cognition	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cambridge Cognition has higher revenue and earnings than Renalytix. Cambridge Cognition is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Renalytix	£3.30M	3.51	-£109.93M	-£4.00	N/A
Cambridge Cognition	£9.40M	1.70	-£1.58M	-£3.90	N/A

Renalytix has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, Cambridge Cognition has a beta of 0.804, indicating that its stock price is 20% less volatile than the broader market.

Cambridge Cognition has a net margin of -17.82% compared to Renalytix's net margin of -680.00%. Renalytix's return on equity of 274.67% beat Cambridge Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Renalytix	-680.00%	274.67%	-93.54%
Cambridge Cognition	-17.82%	-62.89%	-0.30%

In the previous week, Renalytix had 1 more articles in the media than Cambridge Cognition. MarketBeat recorded 2 mentions for Renalytix and 1 mentions for Cambridge Cognition. Cambridge Cognition's average media sentiment score of 0.67 beat Renalytix's score of -0.21 indicating that Cambridge Cognition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Renalytix	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cambridge Cognition	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cambridge Cognition beats Renalytix on 10 of the 16 factors compared between the two stocks.

How does Renalytix compare to Induction Healthcare Group?

Renalytix (LON:RENX) and Induction Healthcare Group (LON:INHC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

In the previous week, Renalytix had 2 more articles in the media than Induction Healthcare Group. MarketBeat recorded 2 mentions for Renalytix and 0 mentions for Induction Healthcare Group. Induction Healthcare Group's average media sentiment score of 0.00 beat Renalytix's score of -0.21 indicating that Induction Healthcare Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Renalytix	Neutral
Induction Healthcare Group	Neutral

14.0% of Renalytix shares are held by institutional investors. Comparatively, 46.3% of Induction Healthcare Group shares are held by institutional investors. 5.1% of Renalytix shares are held by insiders. Comparatively, 54.6% of Induction Healthcare Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Induction Healthcare Group has a net margin of -23.86% compared to Renalytix's net margin of -680.00%. Renalytix's return on equity of 274.67% beat Induction Healthcare Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Renalytix	-680.00%	274.67%	-93.54%
Induction Healthcare Group	-23.86%	-14.58%	-7.32%

Induction Healthcare Group has higher revenue and earnings than Renalytix. Induction Healthcare Group is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Renalytix	£3.30M	3.51	-£109.93M	-£4.00	N/A
Induction Healthcare Group	£12.57M	0.72	-£5.12M	-£5.54	N/A

Renalytix has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, Induction Healthcare Group has a beta of -0.41, indicating that its share price is 141% less volatile than the broader market.

Summary

Induction Healthcare Group beats Renalytix on 7 of the 13 factors compared between the two stocks.

How does Renalytix compare to Feedback?

Renalytix (LON:RENX) and Feedback (LON:FDBK) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Renalytix has a net margin of -680.00% compared to Feedback's net margin of -845.25%. Renalytix's return on equity of 274.67% beat Feedback's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Renalytix	-680.00%	274.67%	-93.54%
Feedback	-845.25%	-135.17%	-22.99%

14.0% of Renalytix shares are owned by institutional investors. Comparatively, 34.7% of Feedback shares are owned by institutional investors. 5.1% of Renalytix shares are owned by insiders. Comparatively, 8.0% of Feedback shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Renalytix has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, Feedback has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

Feedback has lower revenue, but higher earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Feedback, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Renalytix	£3.30M	3.51	-£109.93M	-£4.00	N/A
Feedback	£849.62K	3.35	-£10.84M	-£15.74	N/A

In the previous week, Renalytix had 2 more articles in the media than Feedback. MarketBeat recorded 2 mentions for Renalytix and 0 mentions for Feedback. Feedback's average media sentiment score of 0.00 beat Renalytix's score of -0.21 indicating that Feedback is being referred to more favorably in the news media.

Company	Overall Sentiment
Renalytix	Neutral
Feedback	Neutral

Summary

Renalytix beats Feedback on 7 of the 13 factors compared between the two stocks.

How does Renalytix compare to IQ-AI?

IQ-AI (LON:IQAI) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

14.0% of Renalytix shares are held by institutional investors. 66.0% of IQ-AI shares are held by insiders. Comparatively, 5.1% of Renalytix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

IQ-AI has a beta of 2.25, suggesting that its stock price is 125% more volatile than the broader market. Comparatively, Renalytix has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market.

In the previous week, Renalytix had 2 more articles in the media than IQ-AI. MarketBeat recorded 2 mentions for Renalytix and 0 mentions for IQ-AI. IQ-AI's average media sentiment score of 0.00 beat Renalytix's score of -0.21 indicating that IQ-AI is being referred to more favorably in the media.

Company	Overall Sentiment
IQ-AI	Neutral
Renalytix	Neutral

IQ-AI has higher earnings, but lower revenue than Renalytix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQ-AI	£538.19K	3.30	N/A	N/A	N/A
Renalytix	£3.30M	3.51	-£109.93M	-£4.00	N/A

IQ-AI has a net margin of -77.52% compared to Renalytix's net margin of -680.00%. Renalytix's return on equity of 274.67% beat IQ-AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQ-AI	-77.52%	-140.75%	-22.03%
Renalytix	-680.00%	274.67%	-93.54%

Summary

Renalytix beats IQ-AI on 6 of the 11 factors compared between the two stocks.

How does Renalytix compare to DeepVerge?

DeepVerge (LON:DVRG) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

4.2% of DeepVerge shares are held by institutional investors. Comparatively, 14.0% of Renalytix shares are held by institutional investors. 9.5% of DeepVerge shares are held by company insiders. Comparatively, 5.1% of Renalytix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

DeepVerge has a net margin of -19.81% compared to Renalytix's net margin of -680.00%. Renalytix's return on equity of 274.67% beat DeepVerge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DeepVerge	-19.81%	-10.27%	-5.56%
Renalytix	-680.00%	274.67%	-93.54%

DeepVerge has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than DeepVerge, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DeepVerge	£12.41M	0.00	-£2.46M	-£0.01	N/A
Renalytix	£3.30M	3.51	-£109.93M	-£4.00	N/A

DeepVerge has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Comparatively, Renalytix has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

In the previous week, Renalytix had 2 more articles in the media than DeepVerge. MarketBeat recorded 2 mentions for Renalytix and 0 mentions for DeepVerge. DeepVerge's average media sentiment score of 0.00 beat Renalytix's score of -0.21 indicating that DeepVerge is being referred to more favorably in the media.

Company	Overall Sentiment
DeepVerge	Neutral
Renalytix	Neutral

Summary

DeepVerge beats Renalytix on 7 of the 12 factors compared between the two stocks.

Get Renalytix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RENX vs. The Competition

Export

Metric	Renalytix	Health Information Services Industry	Medical Sector	LON Exchange
Market Cap	£11.58M	£315.49M	£6.92B	£2.83B
Dividend Yield	N/A	5.67%	2.66%	6.15%
P/E Ratio	-0.66	295.76	27.35	369.52
Price / Sales	3.51	137.72	507.73	86,119.00
Price / Cash	1.84	47.14	29.65	27.87
Price / Book	-0.25	7.62	11.06	7.84
Net Income	-£109.93M	-£22.78M	£3.57B	£5.89B
7 Day Performance	32.50%	0.38%	2.56%	0.86%
1 Month Performance	33.84%	1.39%	7.39%	-0.47%
1 Year Performance	-62.14%	-9.19%	34.13%	70.60%

Renalytix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RENX Renalytix	N/A	GBX 2.65 +14.2%	N/A	-66.9%	£11.58M	£3.30M	N/A	102	Gap Down High Trading Volume
COG Cambridge Cognition	1.9503 of 5 stars	GBX 34.93 +2.7%	GBX 56 +60.3%	+6.8%	£16.26M	£9.40M	N/A	80	Gap Up
INHC Induction Healthcare Group	N/A	GBX 9.75 flat	N/A	+0.0%	£9.00M	£12.57M	N/A	74
FDBK Feedback	N/A	GBX 7.04 -0.8%	N/A	-55.2%	£3.09M	£849.62K	N/A	24	Gap Up
IQAI IQ-AI	N/A	GBX 0.80 flat	N/A	+0.0%	£1.77M	£538.19K	N/A	6	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:RENX) was last updated on 7/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Renalytix (RENX) Competitors

RENX vs. COG, INHC, FDBK, IQAI, and DVRG

How does Renalytix compare to Cambridge Cognition?

Summary

How does Renalytix compare to Induction Healthcare Group?

Summary

How does Renalytix compare to Feedback?

Summary

How does Renalytix compare to IQ-AI?

Summary

How does Renalytix compare to DeepVerge?

Summary

Media Sentiment Over Time

RENX vs. The Competition

Renalytix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Renalytix (RENX) Competitors

RENX vs. COG, INHC, FDBK, IQAI, and DVRG

How does Renalytix compare to Cambridge Cognition?

Do insiders & institutionals hold more shares of RENX or COG?

Do analysts rate RENX or COG?

Which has better earnings and valuation, RENX or COG?

Which has more volatility & risk, RENX or COG?

Is RENX or COG more profitable?

Does the media prefer RENX or COG?

Summary

How does Renalytix compare to Induction Healthcare Group?

Does the media prefer RENX or INHC?

Do insiders & institutionals believe in RENX or INHC?

Is RENX or INHC more profitable?

Which has preferable earnings and valuation, RENX or INHC?

Which has more risk & volatility, RENX or INHC?

Summary

How does Renalytix compare to Feedback?

Is RENX or FDBK more profitable?

Do insiders & institutionals have more ownership in RENX or FDBK?

Which has more risk & volatility, RENX or FDBK?

Which has preferable valuation and earnings, RENX or FDBK?

Does the media prefer RENX or FDBK?

Summary

How does Renalytix compare to IQ-AI?

Do insiders and institutionals hold more shares of IQAI or RENX?

Which has more volatility and risk, IQAI or RENX?

Does the media refer more to IQAI or RENX?

Which has higher valuation & earnings, IQAI or RENX?

Is IQAI or RENX more profitable?

Summary

How does Renalytix compare to DeepVerge?

Do insiders & institutionals hold more shares of DVRG or RENX?

Is DVRG or RENX more profitable?

Which has preferable valuation & earnings, DVRG or RENX?

Which has more volatility & risk, DVRG or RENX?

Does the media refer more to DVRG or RENX?

Summary

Media Sentiment Over Time

RENX vs. The Competition

Renalytix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools